摘要
目的观察倍他乐克对扩张型心肌病的临床疗效。方法将127例病员随机分成两组,治疗组(倍他乐克组),在常规标准治疗(利尿剂、ACEI或加用地高辛)上加用β-受体阻滞剂-倍他乐克6.25￣100mg,2次/d,口服;对照组采用常规标准治疗(利尿剂、ACEI或加用地高辛),少数病员短期使用扩血管药物(硝酸脂类)。观察随访病员1.5￣3年,平均(2.00±0.75)年,主要指标:左室舒张末期内径、左室射血分数、6min步行距离,次要指标:心率、收缩压,每6个月复查1次心脏彩超。结果两组临床症状、生活质量均有明显改善(心累、气紧、水肿减轻,可从事轻体力活动),治疗组心脏缩小较对照组明显,左室射血分数、6min步行距离较对照组增加,心率下降较对照组明显,差异有显著性,治疗组死亡率、再住院率较对照组低(P<0.05)。结论倍他乐克治疗扩张型心肌病使患者临床症状、血流动力学改善,提高患者生活质量,降低再住院率与猝死。
[Objective] To observe clinical effect of Metoprolol on dilated cardiomyopathy （DCM）. [Methods] 127 cases patients with DCM were randomized into control group which treated with routine standard therapy （ACEI, Diuretic and digoxin） and Metoprolol group which treated with Metoprolol （12.5-200 mg every day） based on routine standard therapy about 1.5-3 years average（2.00±0.75） years. All patients were followed up mosdy point （LVED, LVEF, MD） and subordination point （HR, SBP）. [Results] Chnical symptom and life quality of two groups were obviously improved after treatment. The level LVEF and MD in patients of Metoprolol group were significantly higher than those in control group （P 〈0.05）, while LVED, heart rate, mortality and hospitalited rate were lower （P 〈0.05）. [Conclusion] Treatment with Metoprolol may improve clinic symptom, hemurrheology, life quality, and decrease hospitalited rate and sudden death of DCM patients.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2007年第1期119-121,共3页
China Journal of Modern Medicine
